Sanofi (SNY) said Thursday China's National Medical Products Administration has approved two company-licensed medicines.
Myqorzo is approved to treat obstructive hypertrophic cardiomyopathy, and Redemplo for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome on the basis of dietary control, the company said.
Hypertrophic cardiomyopathy is an inherited cardiovascular disorder, while familial chylomicronaemia is a severe and rare disease resulting in extremely high triglyceride levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments